MIRM — Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: $521 million for the full year 2025, a 55% increase from $330 million in 2024. Q4 sales were $149 million, up from $99 million year-over-year.
• Operating Expenses: Total operating expenses for 2025 were $543 million, including R&D expenses of $186 million, SG&A expenses of $257 million, and cost of sales of $100 million.
• Cash Position: Ended 2025 with $391 million in cash and equivalents, up from $293 million in 2024. Positive cash flow from operations was achieved in 2025.
• Commercial Cash Contribution Margin: Approximately 55%, reflecting improved profitability.

2. Strategic Updates and Business Highlights

• Product Performance: Strong sales driven by Livmarli ($245 million in the U.S., $115 million internationally) and bile acid medicines ($161 million).
• Pipeline Advancements:
  • Approval of Cholbam for CTX and a tablet formulation of Livmarli.
  • Completion of enrollment in the VISTA study for volixibat in PSC.
  • Addition of brolobitug for chronic hepatitis delta virus, with four potentially registrational clinical readouts expected in the next 18 months.
• Clinical Trials: Positive enrollment trends in ongoing studies for volixibat and other pipeline candidates.

3. Forward Guidance and Outlook

• 2026 Sales Expectations: Projected net product sales between $630 million and $650 million.
• R&D Spending: Anticipated increase in R&D expenses in 2026, primarily due to investments in the brolobitug clinical program and manufacturing validation, fully funded by existing cash reserves.
• Return to Positive Cash Flow: Expected in 2027.

4. Bad News, Challenges, or Points of Concern

• Sales Growth Deceleration: The guidance for 2026 reflects a slower growth rate of 21% to 25%, compared to 55% in 2025, raising concerns about sustaining momentum.
• Market Competition: As new treatments for hepatitis delta virus emerge, including Hepcludex in the U.S. and other dual-agent regimens, competitive pressures may increase.
• Regulatory Risks: Ongoing interactions with the FDA regarding safety database requirements for volixibat could impact the timing of NDA submissions.

5. Notable Q&A Insights

• Pricing Strategy for Volixibat: Management is considering pricing in the context of existing treatments, emphasizing the unique positioning of volixibat due to the lack of approved therapies for PSC.
• Study Design Concerns: Questions raised about the episodic nature of pruritus in PSC patients and how it may affect study outcomes were addressed with confidence in the study design and patient selection criteria.
• Market Size for Brolobitug: The current treatment landscape for hepatitis delta is limited, presenting an opportunity for brolobitug to establish itself as a best-in-class option.
• EXPAND Study Expectations: Management indicated that positive data from the EXPAND study could lead to label expansions, but emphasized the complexity of diagnosing additional cholestatic conditions.

Overall, Mirum Pharmaceuticals demonstrated strong financial performance in 2025, with significant growth in product sales and a robust pipeline. However, challenges related to growth deceleration and competitive pressures in the market were acknowledged, alongside a cautious but optimistic outlook for 2026 and beyond.